Dsg3 CAAR T cells, representing the first cellular immunotherapy for pemphigus vulgaris (PV), are currently under investigation in a Phase 1 trial [12] for patients with mucosal-dominant PV. This evidence concerns the gene DSG3 and pemphigus vulgaris.